Dasanat 50 Mg

Dasatinib belongs to a class of medications known as tyrosine kinase inhibitors, specifically designed to target the BCR-ABL protein, an abnormal enzyme produced by a genetic mutation found in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. By blocking this protein's activity, Dasatinib helps stop the uncontrolled growth and division of cancer cells that rely on this specific pathway. It is commonly used as both a first-line treatment and for patients who have not responded well to or cannot tolerate other tyrosine kinase inhibitors, offering an important option for various stages of CML treatment. Dasatinib is known for its ability to bind to the target protein through a different mechanism than some other medications in its class, which can make it effective even against certain mutations that develop resistance to earlier treatments. As an oral targeted therapy, it offers a more convenient treatment option compared to traditional chemotherapy, allowing much of the treatment to take place at home between clinical check-ins. It is typically taken once daily, following a schedule established by a hematologist or oncologist based on the specific condition and patient response. Regular monitoring, including blood tests and periodic genetic testing, helps track treatment response and guide any necessary adjustments over time. Many patients with CML experience meaningful, long-term disease control with consistent use of Dasatinib as part of their treatment plan. As with all targeted cancer therapies, Dasatinib should be used strictly under the guidance of an experienced hematology or oncology healthcare provider.